Article
RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and MicroRNA expression signatures.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 1 Sept 2012
Mendler Jason H, Maharry Kati, Radmacher Michael D, Mrózek Krzysztof, Becker Heiko, Metzeler Klaus H, Schwind Sebastian, Whitman Susan P, Khalife Jihane, Kohlschmidt Jessica, Nicolet Deedra, Powell Bayard L, Carter Thomas H, Wetzler Meir, Moore Joseph O, Kolitz Jonathan E, Baer Maria R, Carroll Andrew J, Larson Richard A, Caligiuri Michael A, Marcucci Guido, Bloomfield Clara D
Abstract excerpt
PURPOSE: To determine the association of RUNX1 mutations with therapeutic outcome in younger and older patients with primary cytogenetically normal acute myeloid leukemia (CN-AML) and with gene/microRNA expression signatures. PATIENTS AND METHODS: Younger (< 60 years; n = 175) and older (≥ 60 years; n = 225) patients with CN-AML treated with intensive cytarabine/anthracycline-based first-line therapy on Cancer...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.